GTC to terminate Leo Pharma collaboration
This article was originally published in Scrip
Executive Summary
GTC Biotherapeuticsis terminating a development and commercialisation agreement withLeo Pharma for ATryn (antithrombin III [recombinant]), alleging a breach of contract. GTC has notified the Danish firm of its intent to end the collaboration and will seek damages under International Chamber of Commerce arbitration rules.